CDK4/6 dual inhibitor abemaciclib demonstrates compelling preclinical activity against esophageal adenocarcinoma: a novel therapeutic option for a deadly disease

Esophageal adenocarcinoma (EAC) is a deadly disease with limited therapeutic options. In the present study, we determined the preclinical efficacy of CDK4/6 inhibitor abemaciclib for treatment of EAC. In vitro, apoptosis, proliferation, and pathway regulation were evaluated in OE19, OE33, and FLO1 E...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Kosovec, Juliann E., Zaidi, Ali H., Omstead, Ashten N., Matsui, Daisuke, Biedka, Mark J., Cox, Erin J., Campbell, Patrick T., Biederman, Robert W.W., Kelly, Ronan J., Jobe, Blair A.
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2017
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5725031/
https://ncbi.nlm.nih.gov/pubmed/29245989
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.22244
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados